Karyopharm Therapeutics KPTI Stock
Karyopharm Therapeutics Price Chart
Karyopharm Therapeutics KPTI Financial and Trading Overview
| Karyopharm Therapeutics stock price | 1.18 USD |
| Previous Close | 2.09 USD |
| Open | 2.06 USD |
| Bid | 0 USD x 4000 |
| Ask | 0 USD x 3100 |
| Day's Range | 2 - 2.1 USD |
| 52 Week Range | 2 - 6.01 USD |
| Volume | 2.71M USD |
| Avg. Volume | 2.62M USD |
| Market Cap | 236M USD |
| Beta (5Y Monthly) | 0.041901 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.25 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.44 USD |
KPTI Valuation Measures
| Enterprise Value | 286.93M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.090909 |
| PEG Ratio (5 yr expected) | 0.06 |
| Price/Sales (ttm) | 1.593501 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 1.937 |
| Enterprise Value/EBITDA | -2.303 |
Trading Information
Karyopharm Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.041901 |
| 52-Week Change | -53.37% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 6.01 USD |
| 52 Week Low | 2 USD |
| 50-Day Moving Average | 3.01 USD |
| 200-Day Moving Average | 3.85 USD |
KPTI Share Statistics
| Avg. Volume (3 month) | 2.62M USD |
| Avg. Daily Volume (10-Days) | 2.38M USD |
| Shares Outstanding | 114.01M |
| Float | 102.49M |
| Short Ratio | 5.75 |
| % Held by Insiders | 5.02% |
| % Held by Institutions | 90.23% |
| Shares Short | 16.47M |
| Short % of Float | 14.69% |
| Short % of Shares Outstanding | 14.44% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -106.69% |
| Operating Margin (ttm) | -84.61% |
| Gross Margin | 97.22% |
| EBITDA Margin | -84.11% |
Management Effectiveness
| Return on Assets (ttm) | -25.27% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 148.1M USD |
| Revenue Per Share (ttm) | 1.63 USD |
| Quarterly Revenue Growth (yoy) | -18.80% |
| Gross Profit (ttm) | 151.86M USD |
| EBITDA | -124581000 USD |
| Net Income Avi to Common (ttm) | -158018000 USD |
| Diluted EPS (ttm) | -1.73 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 260.38M USD |
| Total Cash Per Share (mrq) | 2.28 USD |
| Total Debt (mrq) | 311.31M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 5.175 |
| Book Value Per Share (mrq) | -0.396 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -109267000 USD |
| Levered Free Cash Flow (ttm) | -50634624 USD |
Profile of Karyopharm Therapeutics
| Country | United States |
| State | MA |
| City | Newton |
| Address | 85 Wells Avenue |
| ZIP | 02459 |
| Phone | 617 658 0600 |
| Website | https://www.karyopharm.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 385 |
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company is also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Q&A For Karyopharm Therapeutics Stock
What is a current KPTI stock price?
Karyopharm Therapeutics KPTI stock price today per share is 1.18 USD.
How to purchase Karyopharm Therapeutics stock?
You can buy KPTI shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Karyopharm Therapeutics?
The stock symbol or ticker of Karyopharm Therapeutics is KPTI.
Which industry does the Karyopharm Therapeutics company belong to?
The Karyopharm Therapeutics industry is Biotechnology.
How many shares does Karyopharm Therapeutics have in circulation?
The max supply of Karyopharm Therapeutics shares is 118.97M.
What is Karyopharm Therapeutics Price to Earnings Ratio (PE Ratio)?
Karyopharm Therapeutics PE Ratio is now.
What was Karyopharm Therapeutics earnings per share over the trailing 12 months (TTM)?
Karyopharm Therapeutics EPS is -1.25 USD over the trailing 12 months.
Which sector does the Karyopharm Therapeutics company belong to?
The Karyopharm Therapeutics sector is Healthcare.
Karyopharm Therapeutics KPTI included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Biotechnology Total Retu XNBI | 4501.69 USD — |
-2.14
|
— — | 4479.13 USD — | 4578.05 USD — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| NASDAQ Composite Total Return I XCMP | 19659.36 USD — |
-1.62
|
— — | 19598.88 USD — | 19861.56 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}